CD19 Antibody (CB19) - BSA Free


Immunocytochemistry/ Immunofluorescence: CD19 Antibody (CB19) [NBP2-25196] - CD19 antibody (CB19) was tested in Non-Hodgkin's lymphoma cells at 1:200 dilution. Green: Alexa Flour 488. Image from verified customer review.
Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on Ramos cells with CD19 Antibody (CB19) NBP2-26646 (blue) and a matched isotype control (orange). Cells were incubated in an antibody more
Immunocytochemistry/ Immunofluorescence: CD19 Antibody (CB19) [NBP2-25196] - The CD19 (CB19) antibody was tested in Daudi cells at a 1:40 dilution against Dylight 488 (Green). Actin and nuclei were counterstained more
Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Surface staining of 10^6 human lymphocytes using 0.2 ug of CD19 antibody (red) and isotype control (green). Cell surface staining kit was used for this test.
Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the FITC conjugate of NBP2-25196. Staining of CD19 in 10^6 human lymphocytes using 10 ul (0.25 ug) of this antibody. Shaded histogram represents cells more
Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the PE conjugate of NBP2-25196. Staining of CD19 in 1x10^6 human PBMC using 10 ul (0.25 ug) of was used to test this product. Propidium iodide negative more
Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the Alexa Fluor (R) 700 conjugate of NBP2-25196. Staining of human PBMC. Image from verified customer review.
Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the DyLight 405 conjugate of NBP2-25196. Staining of CD19 in human PBMCs using anti-CD19 antibody. Image from verified customer review.
Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on human peripheral blood lymphocytes with TACI/TNFRSF13B/CVID (1A1) antibody NB600-1189PE and a matched isotype control. Cells were more
Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on human peripheral blood lymphocytes with CD9 (HI9a) antibody NB100-77915AF647 and a matched isotype control NBP2-27287AF488. Cells were more

Product Details

Reactivity Hu, MuSpecies Glossary
Applications WB, Flow, Func, ICC/IF, CyTOF-ready
BSA Free
1.0 mg/ml

Order Details

CD19 Antibody (CB19) - BSA Free Summary

Intact normal human B cell cells were used as immunogen to generate the CB19 clone.
The exact CD19 epitope recognized by the antibody has not been mapped and is unknown.
Protein G purified
Innovator's Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.


  • CyTOF-ready
  • Flow Cytometry 0.2 ug/10^6 cells
  • Immunocytochemistry/ Immunofluorescence 1:25-1:100
  • In vitro assay reported in scientific literature (PMID 9576485)
  • Western Blot reported in scientific literature (PMID 17327405)
Application Notes
This antibody is CyTOF ready.
Reviewed Applications
Read 1 Review rated 5
NBP2-25196 in the following applications:

Read Publications using
NBP2-25196 in the following applications:

Reactivity Notes

Mouse reactivity reported in scientific literature (PMID: 27532872).

Packaging, Storage & Formulations

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.05% Sodium Azide
1.0 mg/ml
Protein G purified

Alternate Names for CD19 Antibody (CB19) - BSA Free

  • B4
  • B-lymphocyte antigen CD19
  • B-lymphocyte surface antigen B4
  • CD19 antigen
  • CD19 molecule
  • CD19
  • CVID3
  • Differentiation antigen CD19
  • Leu-12
  • MGC12802
  • T-cell surface antigen Leu-12


CD19 (Cluster of Differentiation 19), also known as B-lymphocyte surface antigen B4, is a type 1 transmembrane glycoprotein belonging to immunoglobulin (Ig) subfamily that serves as a biomarker for normal and neoplastic B cells (1,2). CD19 is a co-receptor for the B cell receptor (BCR) signaling complex and has a critical role in regulating B cell signaling and immune response (1,2). The CD19 protein contains an extracellular N-terminus containing two C2 Ig-like domains separated by a helical non-Ig domain, a single pass transmembrane domain, and a highly conserved cytoplasmic C-terminal domain (1,2). The human CD19 protein, encoded by the CD19 gene located on chromosome 16p11.2, is 556 amino acids (aa) in length with a calculated theoretical molecular weight (MW) of 61 kDa and an observed molecular weight of 95 kDa (1-3). CD19 associates with other molecules - CD21, CD81, and CD225 - to form the BCR co-complex, also called the CD19 complex, through CD21 binding to the complement C3d complex (1-3). Complement C3d bridges the BCR with the CD19 complex into lipid rafts of the plasma membrane (1-3). CD19 is capable of modulating B cell development through both BCR-dependent and -independent signaling (1-3). Upon BCR activation, the tyrosine residues of CD19's cytoplasmic tail recruits multiple kinases including Lyn, Vav, and PI3K, amplifying BCR-mediated immune signaling and B cell activation (1-3).

Considering the role of CD19 in BCR signaling and its expression in development from pre-B cells through plasma cells, it is understandable that CD19 dysfunction and abnormal expression is associated with numerous B cell malignancies and autoimmune disorders (1-5). CD19 expression is typically observed at relatively normal levels in B cell acute lymphoblastic leukemia (B-ALL) and chronic lymphoblastic leukemia (CLL) but is often reduced other types of lymphoma including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) (1,2). On the other hand, CD19 expression is typically increased in autoimmune disorders such as systemic sclerosis (SSc) and multiple sclerosis (MS) as modeled by experimental autoimmune encephalomyelitis (EAE) (2). CD19 has become a therapeutic molecular target for the treatment of B cell lymphomas and autoimmune disorders using monoclonal antibodies (mAbs), bi-specific T cell engaging (BiTE) antibodies, and CD19-specific chimeric antigen receptor (CAR) T cells (1,2,4-6). Although anti-CD19 CAR T cell therapy has become the standard for the treatment of B cell malignancies, patients may experience relapse due to resistance mechanisms (6). Strategies to improve efficacy and limit relapse include combination of CAR T cell therapy with immune checkpoint inhibitors like anti-PD-1 (4,6).


1. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36.

2. Li X, Ding Y, Zi M, et al. CD19, from bench to bedside. Immunol Lett. 2017;183:86-95.

3. Wentink MWJ, van Zelm MC, van Dongen JJM, Warnatz K, van der Burg M. Deficiencies in the CD19 complex. Clin Immunol. 2018;195:82-87.

4. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130(4):1586-1594.

5. Penack O, Koenecke C. Complications after CD19+ CAR T-Cell Therapy. Cancers (Basel). 2020;12(11):3445.

6. Bouziana S, Bouzianas D. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Crit Rev Oncol Hematol. 2021;157:103096.


This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customers Who Viewed This Item Also Viewed...

Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, WB
Species: Hu, Mu
Applications: Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Ca, Hu, Mu, Po
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, KD
Species: Hu, Mu
Applications: Flow, WB
Species: Ca, Hu, Mu, Po, Rb, Rt
Applications: Dual ISH-IHC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
Species: Mu, Rt
Applications: Cell Depl, CyTOF-ready, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, InhibTFunc
Species: Hu, Mu
Applications: IHC, IHC-P, WB
Species: Mu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), IHC, IP, WB
Species: Hu
Applications: CyTOF-ready, Flow, IMC, ICC/IF, IHC, IHC-P, WB
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, Func, ICC/IF, IHC, IHC-Fr, IHC-P, IP, In vitro, In vivo, WB
Species: Hu(-), Mu
Applications: ELISA, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Ca, Hu, Pm, Mu, Rt
Applications: ICC/IF, WB
Species: Hu, Mu
Applications: CyTOF-ready, Flow, ICC, KO, Simple Western, WB
Species: Hu
Applications: BA
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
Species: Mu
Applications: ELISA
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: ICC/IF, IHC, IHC-P
Supplier Logo

Publications for CD19 Antibody (NBP2-25196)(11)

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 4 applications: FLOW, ICC/IF, In vitro, WB.

Filter By Application
In vitro
All Applications
Filter By Species
All Species
Showing Publications 1 - 10 of 11. Show All 11 Publications.
Publications using NBP2-25196 Applications Species
Holla S, Prakhar P, Singh V et al. MUSASHI-Mediated Expression of JMJD3, a H3K27me3 Demethylase, Is Involved in Foamy Macrophage Generation during Mycobacterial Infection PLoS Pathog. PLoS Pathog. 2016-08-01 [PMID: 27532872] (Mouse)

This citation used the PE version of this antibody.
Deaglio S, Vaisitti T, Billington R et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells Blood. 2007-06-15 [PMID: 17327405] (ICC/IF, WB, Human) ICC/IF, WB Human
Deaglio S, Vaisitti T, Bergui L et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival Blood. 2005-04-15 [PMID: 15613544] (ICC/IF, FLOW, Human) ICC/IF, FLOW Human
Deaglio S, Capobianco A, Bergui L et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells Blood. 2003-09-15 [PMID: 12763926] (ICC/IF, FLOW, Human) ICC/IF, FLOW Human
Musso T, Deaglio S, Franco L et al. CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines J Leukoc Biol. 2001-04-01 [PMID: 11310847] (Human) Human
Deaglio S, Canella D, Baj G et al. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells Leuk Res. 2001-03-01 [PMID: 11226519]
Zilber MT, Gregory S, Mallone R et al. CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation Proc Natl Acad Sci U S A. 2000-03-14 [PMID: 10706632] (Human) Human
Morra M, Zubiaur M, Terhorst C et al. CD38 is functionally dependent on the TCR/CD3 complex in human T cells FASEB J. 1998-05-01 [PMID: 9576485] (In vitro, Human) In vitro Human
Deaglio S, Morra M, Mallone R et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member J Immunol. 1998-01-01 [PMID: 9551996] (FLOW, Human) FLOW Human
Sorensen EM Plasma-derived exosomes as potential biomarkers for pediatric acute leukemia. Thesis 2020-01-01 (WB, Human)

Exosomes from human plasma samples underwent Western blot analysis.
WB Human
Show All 11 Publications.

Review for CD19 Antibody (NBP2-25196) (1) 51

Average Rating: 5
(Based on 1 review)
We have 1 review tested in 1 species: Human.

Reviews using NBP2-25196:
Filter by Applications
All Applications
Filter by Species
All Species
Images Ratings Applications Species Date Details
Immunocytochemistry CD19 NBP2-25196
reviewed by:
Verified Customer
ICC Human 12/15/2021


Sample TestedNon-Hodgkin's lymphoma cells

Product General Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

Video Protocols

WB Video Protocol
ICC/IF Video Protocol

FAQs for CD19 Antibody (NBP2-25196) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Secondary Antibodies


Isotype Controls

Additional CD19 Products

Diseases for CD19 Antibody (NBP2-25196)

Discover more about diseases related to CD19 Antibody (NBP2-25196).

Pathways for CD19 Antibody (NBP2-25196)

View related products by pathway.

PTMs for CD19 Antibody (NBP2-25196)

Learn more about PTMs related to CD19 Antibody (NBP2-25196).

Research Areas for CD19 Antibody (NBP2-25196)

Find related products by research area.

Blogs on CD19.

Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy
By Victoria Osinski, PhDWhat’s “Natural” About Natural Killer (NK) Cells?For immunologists, the term cytotoxicity often conjures up images of an army of antigen specific CD8+ T cells deploying to ...  Read full blog post.

How To Identify B Cell Subsets Using Flow Cytometry
By Victoria OsinskiUsing Flow Cytometry to Identify B Cell SubsetsIdentifying cellular subsets by flow cytometry requires careful and thorough planning in order to ensure the correct subset of cells are identified...  Read full blog post.

Antigen-loss relapse after successful CAR-T therapy; What do we do now?
By Jacqueline Carrico, BS, MD Tumor cell mechanisms driving tolerance to CAR-T Despite very promising results of CAR-T therapy in acute lymphoblastic leukemia, B-ALL, antigen-loss relapse has arisen as a major chall...  Read full blog post.

CD19: An Undoubted Biomarker for B Cells
CD19 is a cell surface protein member of the large immunoglobulin superfamily that complexes with CD21, CD81, and CD225 in the membrane of mature B-cells. A major function of CD19 is to assemble with the antigen receptor of B-lymphocytes to decrease t...  Read full blog post.

mFluor Violet Conjugated Antibodies

Customers Who Bought This Also Bought

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Recent Reviews


Verified Customer
Application: ICC
Species: Human


Gene Symbol CD19